Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...